Clinical Trial

Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

Study acronym: DAN-COVID
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-11.
Status change: Recruiting → Active, Not Recruiting 2026-03-13
Trial Details
NCT Number NCT07279766
Lead Sponsor Tor Biering-Sørensen
Collaborators: ModernaTX, Inc.
Conditions COVID-19
Enrollment 285,000 participants
Start Date 2025-12-11
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-16